Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current...

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment.
• Pre-clinical data suggest EGFR-driven non-small cell lung cancer (NSCLC) suppresses antitumor immunity via PD-1/PD-L1, yet epidemiological studies indicate EGFR mutations correlate with lower PD-L1 expression.
• The efficacy of single-agent PD-1/PD-L1 inhibitors in pre-treated EGFR-mutant NSCLC is debated, with proposed reasons including lower tumor mutational burden and an immunosuppressive tumor microenvironment.

Purpose of the Study:

• To review the current understanding of the interplay between EGFR mutations and immune checkpoint inhibitor response in NSCLC.
• To highlight the need for predictive biomarkers for ICI sensitivity in EGFR-mutant NSCLC.
• To discuss the ongoing investigation of combination therapies involving EGFR TKIs and ICIs.

Main Methods:

• Literature review of pre-clinical studies, epidemiological data, and clinical trial outcomes.
• Analysis of proposed mechanisms for poor response to ICIs in EGFR-mutant NSCLC.
• Synthesis of current research on combination therapies and their associated toxicities.

Main Results:

• The effectiveness of PD-1/PD-L1 inhibitors as monotherapy in EGFR-mutant NSCLC is variable and potentially moderated.
• Factors contributing to poor ICI response include lower tumor mutation burden and an immunosuppressive tumor microenvironment.
• Early combination therapy studies report increased toxicities, necessitating careful evaluation.

Conclusions:

• Predictive biomarkers are crucial for identifying EGFR-mutant NSCLC patients likely to benefit from PD-1/PD-L1 inhibitors.
• The optimal use of combination EGFR TKI and ICI therapy, including sequencing, scheduling, and dosing, remains undetermined and is under intensive clinical investigation.
• Further research and careful evaluation are required to balance efficacy and toxicity in combined treatment strategies for EGFR-mutant NSCLC.